Nosocomial Infections - Market Insight, Epidemiology and Market Forecast - 2027

Nosocomial Infections - Market Insight, Epidemiology and Market Forecast - 2027

Category

Pharmaceuticals

Published Date

1st Feb 2018

Pages

100

Choose License

Final Price

DelveInsight's "Nosocomial Infections - Market Insight, Epidemiology and Market Forecast - 2027" report provides a detailed analysis of the Nosocomial Infections epidemiology and market outlook for the 7MM.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

Nosocomial Infections Understanding and Treatment Algorithm
The market report provides the overview of the Nosocomial Infections by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Nosocomial Infections Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Nosocomial Infections in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Nosocomial Infections Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Nosocomial Infections Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Nosocomial Infections market.

Nosocomial Infections Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2027. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Nosocomial Infections Report Insights
• Patient Population in Nosocomial Infections
• Therapeutic Approaches in Nosocomial Infections
• Nosocomial Infections Pipeline Analysis
• Nosocomial Infections Market Size and Trends
• Nosocomial Infections Market Opportunities
• Impact of upcoming Therapies in Nosocomial Infections

Nosocomial Infections Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Nosocomial Infections Report Assessment
• Current Treatment Practices in Nosocomial Infections
• Unmet Needs in Nosocomial Infections
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• The report will help to develop Business Strategies by understanding the trends shaping and driving the Nosocomial Infections market
• Organize sales and marketing efforts by identifying the best opportunities for Nosocomial Infections market
• To understand the future market competition in the Nosocomial Infections market.
1. Report Introduction
2. Nosocomial Infections Market Overview at a Glance
2.1. Market Share Distribution of Nosocomial Infections in 2017
2.2. Market Share Distribution of Nosocomial Infections in 2027
3. Disease Background and Overview: Nosocomial Infections
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Nosocomial Infections in 7MM
4.3. Total Prevalent Patient Population of Nosocomial Infections in 7MM – By Countries
5. Epidemiology of Nosocomial Infections by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Nosocomial Infections
5.1.3. Sub-Type Specific cases of the Nosocomial Infections *
5.1.4. Sex- Specific Cases of the Nosocomial Infections *
5.1.5. Diagnosed Cases of the Nosocomial Infections
5.1.6. Treatable Cases of the Nosocomial Infections
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Nosocomial Infections
5.4.3. Sub-Type Specific cases of the Nosocomial Infections *
5.4.4. Sex- Specific Cases of the Nosocomial Infections *
5.4.5. Diagnosed Cases of the Nosocomial Infections
5.4.6. Treatable Cases of the Nosocomial Infections
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Nosocomial Infections
5.5.3. Sub-Type Specific cases of the Nosocomial Infections *
5.5.4. Sex- Specific Cases of the Nosocomial Infections *
5.5.5. Diagnosed Cases of the Nosocomial Infections
5.5.6. Treatable Cases of the Nosocomial Infections
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Nosocomial Infections
5.6.3. Sub-Type Specific cases of the Nosocomial Infections *
5.6.4. Sex- Specific Cases of the Nosocomial Infections *
5.6.5. Diagnosed Cases of the Nosocomial Infections
5.6.6. Treatable Cases of the Nosocomial Infections
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Nosocomial Infections
5.7.3. Sub-Type Specific cases of the Nosocomial Infections *
5.7.4. Sex- Specific Cases of the Nosocomial Infections *
5.7.5. Diagnosed Cases of the Nosocomial Infections
5.7.6. Treatable Cases of the Nosocomial Infections
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Nosocomial Infections
5.8.3. Sub-Type Specific cases of the Nosocomial Infections *
5.8.4. Sex- Specific Cases of the Nosocomial Infections *
5.8.5. Diagnosed Cases of the Nosocomial Infections
5.8.6. Treatable Cases of the Nosocomial Infections
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Nosocomial Infections
5.9.3. Sub-Type Specific cases of the Nosocomial Infections *
5.9.4. Sex- Specific Cases of the Nosocomial Infections *
5.9.5. Diagnosed Cases of the Nosocomial Infections
5.9.6. Treatable Cases of the Nosocomial Infections
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Nosocomial Infections
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Nosocomial Infections
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Nosocomial Infections : 7MM Market Analysis
12.1. 7MM Market Size of Nosocomial Infections
12.2. 7MM Percentage Share of drugs marketed for Nosocomial Infections
12.3. 7MM Market Sales of Nosocomial Infections by Products
13. Nosocomial Infections : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Nosocomial Infections in United States
13.1.2. Percentage Share of drugs marketed for Nosocomial Infections in United States
13.1.3. Market Sales of Nosocomial Infections by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Nosocomial Infections in Germany
13.2.1.2. Percentage Share of drugs marketed for Nosocomial Infections in Germany
13.2.1.3. Market Sales of Nosocomial Infections by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Nosocomial Infections in France
13.2.2.2. Percentage Share of drugs marketed for Nosocomial Infections in France
13.2.2.3. Market Sales of Nosocomial Infections by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Nosocomial Infections in Italy
13.2.3.2. Percentage Share of drugs marketed for Nosocomial Infections in Italy
13.2.3.3. Market Sales of Nosocomial Infections by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Nosocomial Infections in Spain
13.2.4.2. Percentage Share of drugs marketed for Nosocomial Infections in Spain
13.2.4.3. Market Sales of Nosocomial Infections by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Nosocomial Infections in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Nosocomial Infections in United Kingdom
13.2.5.3. Market Sales of Nosocomial Infections by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Nosocomial Infections in Japan
13.3.2. Percentage Share of drugs marketed for Nosocomial Infections in Japan
13.3.3. Market Sales of Nosocomial Infections by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific
Table 1: Total Prevalent/Incident Cases of the Nosocomial Infections in 7MM
Table 2: Total Prevalent/Incident Cases of the Nosocomial Infections in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Nosocomial Infections in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Nosocomial Infections in United States (2016-2027)
Table 5: Sex- Specific Cases of the Nosocomial Infections in United States (2016-2027)
Table 6: Diagnosed Cases of the Nosocomial Infections in United States (2016-2027)
Table 7: Treatable Cases of the Nosocomial Infections in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Nosocomial Infections in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Nosocomial Infections in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Nosocomial Infections in Germany (2016-2027)
Table 11: Diagnosed Cases of the Nosocomial Infections in Germany (2016-2027)
Table 12: Treatable Cases of the Nosocomial Infections in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Nosocomial Infections in France (2016-2027)
Table 14: Sub-Type Specific cases of the Nosocomial Infections in France (2016-2027)
Table 15: Sex- Specific Cases of the Nosocomial Infections in France (2016-2027)
Table 16: Diagnosed Cases of the Nosocomial Infections in France (2016-2027)
Table 17: Treatable Cases of the Nosocomial Infections in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Nosocomial Infections in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Nosocomial Infections in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Nosocomial Infections in Italy (2016-2027)
Table 21: Diagnosed Cases of the Nosocomial Infections in Italy (2016-2027)
Table 22: Treatable Cases of the Nosocomial Infections in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Nosocomial Infections in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Nosocomial Infections in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Nosocomial Infections in Spain (2016-2027)
Table 26: Diagnosed Cases of the Nosocomial Infections in Spain (2016-2027)
Table 27: Treatable Cases of the Nosocomial Infections in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Nosocomial Infections in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Nosocomial Infections in UK (2016-2027)
Table 30: Sex- Specific Cases of the Nosocomial Infections in UK (2016-2027)
Table 31: Diagnosed Cases of the Nosocomial Infections in UK (2016-2027)
Table 32: Treatable Cases of the Nosocomial Infections in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Nosocomial Infections in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Nosocomial Infections in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Nosocomial Infections in Japan (2016-2027)
Table 36: Diagnosed Cases of the Nosocomial Infections in Japan (2016-2027)
Table 37: Treatable Cases of the Nosocomial Infections in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Nosocomial Infections in USD MM (2016-2027)
Table 42:7MM- Market Share Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Nosocomial Infections in USD MM (2016-2027)
Table 45: United States-Market Share Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Nosocomial Infections in USD MM (2016-2027)
Table 48: Germany-Market Share Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Nosocomial Infections in USD MM (2016-2027)
Table 51: France-Market Share Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Nosocomial Infections in USD MM (2016-2027)
Table 54: Italy-Market Share Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Nosocomial Infections in USD MM (2016-2027)
Table 57: Spain-Market Share Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Nosocomial Infections in USD MM (2016-2027)
Table 60:UK-Market Share Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Nosocomial Infections in USD MM (2016-2027)
Table 63: Japan-Market Share Nosocomial Infections by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Nosocomial Infections by Therapies in USD MM (2016-2027)

Get Free Sample

You can get a FREE sample of any report. Just click the "Free Sample" link.

Explore Latest Reports

If you have any special requirement or looking for more discounts, Kindly contact our sales team

Contact Us